After getting crushed by bad data, Zynerba says its cannabis-based drug worked on Fragile X symptoms
Less than two months since a pair of mid-stage setbacks crushed its stock price, researchers at Zynerba $ZYNE say they had better results from a small Phase II study that tested their cannabis-based therapy on symptoms of Fragile X syndrome. And the news quickly sparked a big rally for its battered stock.
Often compared to GW Pharmaceuticals, which has had some striking successes in the field, Zynerba set out to see what impact their cannabidiol therapy would have tamping down on a range of common symptoms for Fragile X, including anxiety and depression. And with 20 patients in the single-arm study, the investigators say they hit their primary with a 46% drop in their ADAMS score, tracking Anxiety, Depression, and Mood Scale.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
